Stocks TelegraphStocks Telegraph
Stock Ideas

ST Premium

Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Try Now for Just $1!

EVOK Financial Statements and Analysis

NASDAQ : EVOK

Evoke Pharma, Inc.

$2.15
0.03+1.42%
At Close 4:00 PM
61.44
B-ESG ScoreESG Rating

EVOK FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

EVOK Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

DateSep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
revenue2.654M2.551M1.735M1.676M1.563M
cost of revenue104.024K41.478K92.529K59.024K34.908K
gross profit2.55M2.51M1.643M1.617M1.528M
gross profit ratio0.9610.9840.9470.9650.978
research and development expenses11.677K04.645K22.56K0
general and administrative expenses00000
selling and marketing expenses00000
selling general and administrative expenses3.824M3.733M3.14M3.482M3.131M
other expenses041.478K92.529K034.908K
operating expenses3.836M3.733M3.144M3.505M3.131M
cost and expenses3.94M3.775M3.237M3.564M3.166M
interest income99.294K81.001K46.058K26.544K35.558K
interest expense126.027K124.657K124.658K126.027K126.028K
depreciation and amortization99.294K1.224M1.501M1.888M35.558K
ebitda-1.186M-1.143M0-1.888M-1.568M
ebitda ratio-0.447-0.48-0.865-1.126-1.003
operating income-1.286M-1.224M-1.501M-1.888M-1.603M
operating income ratio-0.484-0.48-0.865-1.126-1.026
total other income expenses net-26.733K-43.656K-78.60K-99.481K-90.47K
income before tax-1.312M-1.267M-1.58M-1.987M-1.694M
income before tax ratio-0.494-0.497-0.91-1.186-1.084
income tax expense0-1.224M-1.501M-1.888M0
net income-1.312M-1.267M-1.58M-1.987M-1.694M
net income ratio-0.494-0.497-0.91-1.186-1.084
eps-0.94-0.93-2.09-0.59-0.51
eps diluted-0.94-0.93-2.09-0.59-0.51
weighted average shs out1.40M1.364M756.844K3.343M3.343M
weighted average shs out dil1.40M1.364M756.844K3.343M3.343M
Graph

EVOK Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

DateSep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
cash and cash equivalents11.339M9.178M9.703M4.739M5.965M
short term investments00000
cash and short term investments11.339M9.178M9.703M4.739M5.965M
net receivables2.023M2.003M1.452M673.071K1.234M
inventory493.408K544.765K588.776K481.84K504.925K
other current assets183.125K410.611K710.527K932.572K98.094K
total current assets14.038M12.136M12.454M6.827M7.84M
property plant equipment net000013.37K
goodwill00000
intangible assets00000
goodwill and intangible assets00000
long term investments00000
tax assets00000
other non current assets115.488K00241.637K0
total non current assets115.488K00241.637K13.37K
other assets00000
total assets14.154M12.136M12.454M7.069M7.853M
account payables2.188M1.90M1.64M1.712M1.397M
short term debt5.00M5.00M5.00M013.37K
tax payables00000
deferred revenue0000-1.397M
other current liabilities2.578M2.571M2.317M1.324M2.227M
total current liabilities9.766M9.471M8.957M3.036M2.24M
long term debt0005.00M5.00M
deferred revenue non current00000
deferred tax liabilities non current00000
other non current liabilities0001.612M1.486M
total non current liabilities006.737M6.612M6.486M
other liabilities00-6.737M00
capital lease obligations000013.37K
total liabilities9.766M9.471M8.957M9.648M8.727M
preferred stock00000
common stock89.0073.00859.00334.00334.00
retained earnings-127.599M-126.286M-125.019M-123.439M-121.452M
accumulated other comprehensive income loss00000
other total stockholders equity131.986M128.951M128.516M120.86M120.578M
total stockholders equity4.387M2.665M3.497M-2.58M-873.775K
total equity4.387M2.665M3.497M-2.58M-873.775K
total liabilities and stockholders equity14.154M12.136M12.454M7.069M7.853M
minority interest00000
total investments00000
total debt5.00M5.00M5.00M5.00M5.013M
net debt-6.339M-4.178M-4.703M260.574K-951.456K
Graph

EVOK Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

DateSep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
deferred income tax00000
stock based compensation131.587K126.578K254.029K281.639K281.758K
change in working capital1.183M195.368K-1.378M586.288K331.072K
accounts receivables-19.515K-551.099K-778.833K560.833K-210.091K
inventory51.357K44.011K-106.936K-192.462K342.293K
accounts payables-188.084K242.624K343.596K191.996K-17.867K
other working capital376.252K459.832K-836.084K25.921K216.737K
other non cash items-820.781K515.699K920.86K13.37K39.472K
net cash provided by operating activities-818.695K-820.615K-2.579M-1.106M-1.042M
investments in property plant and equipment5.00-5.00000
acquisitions net00000
purchases of investments00000
sales maturities of investments00000
other investing activites00000
net cash used for investing activites5.000000
debt repayment0000-39.472K
common stock issued-7.838M295.696K7.543M-119.296K0
common stock repurchased-3.266M3.266M000
dividends paid00000
other financing activites14.084M295.696K-426.293K00
net cash used provided by financing activities2.98M295.696K7.543M-119.296K-39.472K
effect of forex changes on cash00000
net change in cash2.161M-524.919K4.963M-1.225M-1.042M
cash at end of period11.339M9.178M9.703M4.739M5.965M
cash at beginning of period9.178M9.703M4.739M5.965M7.006M
operating cashflow-818.695K-820.615K-2.579M-1.106M-1.042M
capital expenditure5.00-5.00000
free cash flow-818.69K-820.62K-2.579M-1.106M-1.042M
Graph

Frequently Asked Questions

How did Evoke Pharma, Inc. do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, EVOK generated $2.65M in revenue last quarter, while its costs came in at $104.02K.
Last quarter, how much Gross Profit did Evoke Pharma, Inc. report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Evoke Pharma, Inc. reported a $2.55M Gross Profit for the quarter ended Sep 30, 2024.
Have EVOK's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. EVOK incurred $3.84M worth of Operating Expenses, while it generated -$1.29M worth of Operating Income.
How much Net Income has EVOK posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Evoke Pharma, Inc., the company generated -$1.31M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did Evoke Pharma, Inc. have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Evoke Pharma, Inc. as of the end of the last quarter was $11.34M.
What are EVOK's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, EVOK had Total Net Receivables of $2.02M.
In terms of Total Assets and Current Assets, where did Evoke Pharma, Inc. stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of EVOK were $14.04M, while the Total Assets stand at $14.15M.
As of the last quarter, how much Total Debt did Evoke Pharma, Inc. have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of EVOK's debt was $5.00M at the end of the last quarter.
What were EVOK's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, EVOK reported total liabilities of $9.77M.
How much did EVOK's Working Capital change over the last quarter?
Working Capital Change for EVOK was $1.18M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
EVOK generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. EVOK generated -$818.70K of Cash from Operating Activities during its recently reported quarter.
What was EVOK's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. EVOK reported a $2.16M Net Change in Cash in the most recent quarter.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph